Angiogenesis Foundation: Leading the Charge in Angiogenesis
Posted by Charity Watcher on Tuesday, November 3, 2015
The Angiogenesis Foundation, a Cambridge, Massachusetts-based non-profit organization founded in 1994, is at the frontlines of the study of angiogenesis. Its main focus is on the search for cost-efficient, results-effective treatments for cancer as well as on the areas of dermatology, cardiology and ophthalmology. It has already developed an effective therapy for canine cancer known as the Navy Protocol, which kills the tumor by starving it of its blood supply.
Angiogenesis refers to the growth of new capillary blood vessels, which studies have identified as the “common denominator” in many of humanity’s most feared diseases. By restoring the healthy balance in blood vessel growth, the foundation continues to help people lead healthier and longer lives. For this approach, it is considered as one of the most unique medical organizations in the world as well as acknowledged as the champion of the new field of medicine.
The foundation has achieved many milestones in its mission. In 1998, it led in the establishment of an angiogenic growth factor therapy, the world’s first advanced treatment for foot ulcers among diabetics. In 2004, it helped in the public launch of the world’s first antiangiogenic therapy for colorectal cancer, which was later expanded to include cancers in the breast, lng, kidney, liver, and brain.
The foundation has also established partnerships with other scientific organizations in the pursuit of its mission. It organized the first annual international research conference that brought leaders tin medicine, science and industry as well as government to discuss the developments in the fight against cancer, among other diseases that can be treated via angiogenesis-based therapy. It also launched the first research program designed toward the systematic identification and testing of antiangiogenic molecules in food and beverages.
Other achievements include the development of an antiangiogenic cream against skin cancers; the demonstration of the efficacy of angiogenesis in the regeneration of lost tissues essential in wound healing; and in the study of angiogenesis in the treatment of animal cancers.
Angiogenesis refers to the growth of new capillary blood vessels, which studies have identified as the “common denominator” in many of humanity’s most feared diseases. By restoring the healthy balance in blood vessel growth, the foundation continues to help people lead healthier and longer lives. For this approach, it is considered as one of the most unique medical organizations in the world as well as acknowledged as the champion of the new field of medicine.
The foundation has achieved many milestones in its mission. In 1998, it led in the establishment of an angiogenic growth factor therapy, the world’s first advanced treatment for foot ulcers among diabetics. In 2004, it helped in the public launch of the world’s first antiangiogenic therapy for colorectal cancer, which was later expanded to include cancers in the breast, lng, kidney, liver, and brain.
The foundation has also established partnerships with other scientific organizations in the pursuit of its mission. It organized the first annual international research conference that brought leaders tin medicine, science and industry as well as government to discuss the developments in the fight against cancer, among other diseases that can be treated via angiogenesis-based therapy. It also launched the first research program designed toward the systematic identification and testing of antiangiogenic molecules in food and beverages.
Other achievements include the development of an antiangiogenic cream against skin cancers; the demonstration of the efficacy of angiogenesis in the regeneration of lost tissues essential in wound healing; and in the study of angiogenesis in the treatment of animal cancers.
